Log In
BCIQ
Print this Print this
 

EMD 640744

Also known as: Survivac

  Manage Alerts
Collapse Summary General Information
Company Merck KGaA
DescriptionVaccine targeting survivin-expressing solid tumors
Molecular Target Survivin (BIRC5)
Mechanism of ActionVaccine
Therapeutic Modality 
Latest Stage of DevelopmentPhase I
Standard IndicationSolid tumors
Indication DetailsTreat solid tumors
Regulatory Designation
PartnerImmunovaccine Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

07/19/2010

Undisclosed

0

Undisclosed

Get a free BioCentury trial today